(Q34155594)

31 July 2017

Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function (English)

1 reference

31 July 2017

0 references

Frank J Accurso

1

1 reference

31 July 2017

Richard B Moss

2

1 reference

31 July 2017

Robert W Wilmott

3

1 reference

31 July 2017

Ran D Anbar

4

1 reference

31 July 2017

Amy E Schaberg

5

1 reference

31 July 2017

Todd A Durham

6

1 reference

31 July 2017

Bonnie W Ramsey

7

1 reference

31 July 2017

TIGER-1 Investigator Study Group

8

1 reference

31 July 2017

language of work or name

English

0 references

publication date

17 December 2010

1 reference

American Journal of Respiratory and Critical Care Medicine

31 July 2017

1 reference

31 July 2017

183

1 reference

31 July 2017

5

1 reference

31 July 2017

627-634

1 reference

CFTR function and prospects for therapy

31 July 2017

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Evidence for airway surface dehydration as the initiating event in CF airway disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Lung function from infancy to the preschool years after clinical diagnosis of cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Structural airway abnormalities in infants and young children with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Cystic fibrosis lung disease starts in the small airways: can we treat it more effectively?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Early detection of lung disease in children with cystic fibrosis using lung function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

TMEM16A confers receptor-activated calcium-dependent chloride conductance

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Expression cloning of TMEM16A as a calcium-activated chloride channel subunit

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Transmembrane protein 16A (TMEM16A) is a Ca2+-regulated Cl- secretory channel in mouse airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Purinergic receptors in airway epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Early referral to cystic fibrosis specialist centre impacts on respiratory outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Defining a pulmonary exacerbation in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Pulmonary function between 6 and 18 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Spirometric reference values from a sample of the general U.S. population

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Reference ranges for spirometry across all ages: a new approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

Lung Function in Infants with Cystic Fibrosis Diagnosed by Newborn Screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201008-1267OC

10.1164/RCCM.201008-1267OC

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference